Scarica l'app Stockscreener
22.05
1.17%
-0.26
Dopo l'orario di chiusura:
22.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$22.31
Aprire:
$22.23
Volume 24 ore:
1.34M
Relative Volume:
0.47
Capitalizzazione di mercato:
$2.79B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-10.86
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-2.26%
1M Prestazione:
-4.96%
6M Prestazione:
-7.74%
1 anno Prestazione:
-22.66%
Intervallo 1D:
$21.72
$22.38
Intervallo di 1 settimana:
$21.71
$23.69
Portata 52W:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.05 | 2.82B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2026-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
(APLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Apellis Pharmaceuticals (APLS) Valuation Check After Recent S&P 1000 Index Inclusion - Yahoo Finance
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC - MarketBeat
ING Groep NV Acquires 866,200 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Market Overview: Will Apellis Pharmaceuticals Inc outperform the market in YEARWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS) - simplywall.st
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions - Sahm
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
How Empaveli’s Rapid Uptake and Q4 2025 Revenue Momentum Will Impact Apellis Pharmaceuticals (APLS) Investors - Sahm
(APLS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential - Finviz
Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsShort Setup & Reliable Intraday Trade Alerts - mfd.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded to Hold at Barclays - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
J. Safra Sarasin Holding AG Sells 45,184 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Equal-Weight Rating from Barclays | APLS Stock News - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Barclays - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 56.89% Upside Potential - DirectorsTalk Interviews
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
A Look At Apellis Pharmaceuticals (APLS) Valuation As GAAP Profitability And Syfovre Commercialization Gain Traction - Yahoo Finance
Apellis Turns GAAP Profitable As Syfovre Sales Shift Story To Execution - Sahm
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp. - MarketBeat
Value Recap: Is BAFN a strong growth stockGap Up & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Buybacks Report: Will Apellis Pharmaceuticals Inc. benefit from geopolitical trendsQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Apellis upgraded at BofA on launch trajectory for kidney disease therapy - MSN
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Apellis Pharma CEO Francois sells $592k in shares By Investing.com - Investing.com Canada
Caroline Baumal Sells 2,797 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David Watson Sells 7,832 Shares - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 2,064 Shares of Stock - MarketBeat
Timothy Eugene Sullivan Sells 10,287 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis stock surges after Sobi $300 million royalty deal - MSN
Aug Retail: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialSell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy - ChartMill
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock - Investing.com Nigeria
Apellis Pharma CMO Baumal sells $37k in shares By Investing.com - Investing.com India
Nicholson nur, Apellis Pharmaceuticals CTO, sells $43k in APLS stock By Investing.com - Investing.com South Africa
Apellis Pharma VP Chopas sells $14k in shares By Investing.com - Investing.com Canada
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells 8,182 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $26,399.86 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 909 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 1,882 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 2,475 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 2,892 Shares of Stock - MarketBeat
Apellis Pharmaceuticals' Empaveli Approved, Projected $508 Million Sales by 2033 - Intellectia AI
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apellis Pharmaceuticals Inc Azioni (APLS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Francois Cedric | Chief Executive Officer |
Feb 03 '26 |
Option Exercise |
3.76 |
8,840 |
33,238 |
490,837 |
| Baumal Caroline | Chief Medical Officer |
Jan 22 '26 |
Sale |
21.77 |
2,797 |
60,878 |
86,527 |
| Chopas James George | VP/Chief Accounting Officer |
Jan 22 '26 |
Sale |
21.77 |
2,064 |
44,924 |
49,805 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer |
Jan 22 '26 |
Sale |
21.77 |
3,371 |
73,371 |
78,353 |
| Deschatelets Pascal | Chief Scientific Officer |
Jan 22 '26 |
Sale |
21.77 |
5,928 |
129,025 |
1,151,382 |
| Francois Cedric | Chief Executive Officer |
Jan 22 '26 |
Sale |
21.77 |
27,192 |
591,845 |
286,045 |
| Nicholson Nur | Chief Technical Officer |
Jan 22 '26 |
Sale |
21.77 |
7,725 |
168,138 |
71,118 |
| Sullivan Timothy Eugene | Chief Financial Officer |
Jan 22 '26 |
Sale |
21.77 |
10,287 |
223,901 |
93,901 |
| Watson David O. | General Counsel |
Jan 22 '26 |
Sale |
21.77 |
7,832 |
170,467 |
88,531 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):